Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company's products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Type
Public
HQ
Bedford, US
Founded
2006
Size (employees)
118 (est)
Website
ocutx.com
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, US
Report incorrect company information

Key People/Management at Ocular Therapeutix

Antony Mattessich

Antony Mattessich

Chief Executive Officer
Fred Khosravi

Fred Khosravi

Co - Founder, Director & Chairman

Ocular Therapeutix Office Locations

Ocular Therapeutix has an office in Bedford
Bedford, US (HQ)
36 Crosby Drive,
Show all (1)
Report incorrect company information

Ocular Therapeutix Financials and Metrics

Ocular Therapeutix Financials

Ocular Therapeutix's revenue was reported to be $1.92 m in FY, 2017
USD

Revenue (FY, 2017)

1.9 m

Net income (FY, 2017)

(63.4 m)

EBIT (FY, 2017)

(61.9 m)

Market capitalization (23-Apr-2018)

183.7 m

Cash (31-Dec-2017)

41.5 m
Ocular Therapeutix's current market capitalization is $183.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

772 k1.8 m1.9 m

Revenue growth, %

127%

Sales and marketing expense

17 m

General and administrative expense

15.5 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

37.4 m30.8 m32.9 m41.5 m

Accounts Receivable

329 k193 k250 k226 k

Inventories

893 k1.6 m1.4 m122 k

Current Assets

76.2 m107 m69.9 m43.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

19.9 m80.9 m12.5 m78.7 m41.2 m46.2 m48.2 m52.2 m54.7 m63 m

Accounts Receivable

60 k53 k352 k164 k189 k227 k223 k243 k244 k211 k

Inventories

109 k117 k158 k145 k147 k127 k149 k126 k96 k90 k

Current Assets

22.6 m82.3 m69.5 m126.6 m115.9 m97.1 m85 m76.8 m83.3 m68.3 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6 m)(39.7 m)(44.7 m)(63.4 m)

Depreciation and Amortization

547 k754 k881 k1.6 m

Inventories

(36 k)(53 k)924 k(9 k)

Accounts Payable

507 k348 k(159 k)932 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)(34.7 m)

Depreciation and Amortization

244 k383 k173 k360 k554 k205 k412 k628 k261 k615 k

Inventories

(109 k)(117 k)(25 k)(12 k)(14 k)7 k(15 k)8 k17 k23 k

Accounts Payable

345 k63 k153 k651 k(360 k)79 k(462 k)(289 k)659 k2.9 m
USDY, 2017

Revenue/Employee

16.3 k

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information

Ocular Therapeutix News and Updates

Unable to head off the FDA, Ocular Therapeutix gets second CRL for eye drug

Manufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery.
Report incorrect company information